Home > People

Vincent L. Capuano, Ph.D.
Partner
Duane Morris LLP
Suite 500
470 Atlantic Avenue
Boston, MA 02210-2243
USA

Phone: +1 857 488 4250
Fax: +1 857 401 3002
Email: vcapuano@duanemorris.com

Vincent L. Capuano, Ph.D., practices in the area of intellectual property law, with a focus on patent law in the chemical and pharmaceutical industries and an emphasis on representing generic pharmaceutical companies filing Abbreviated New Drug Applications (ANDA) with the U.S. Food and Drug Administration. Dr. Capuano has extensive experience representing pharmaceutical companies in prelitigation strategic planning and patent litigation. Dr. Capuano also counsels clients in all areas of patent procurement, exploitation and enforcement, including domestic and foreign patent preparation and procurement, patent validity and infringement analysis, patent licensing and due diligences.

Prior to entering the practice of law, Dr. Capuano was an Innoue Foundation for Science postdoctoral fellow at Hiroshima University School of Medicine in Hiroshima, Japan, and an NIH/CNRS postdoctoral fellow at the Université Louis Pasteur in Strasbourg, France.

Dr. Capuano is a 1999 graduate of the University of Akron School of Law and a graduate of the University of Texas at Austin (Ph.D., Organic Chemistry, 1991) and Ohio State University (B.S., Chemistry, 1987).

Areas of Practice

• Intellectual Property
• Patents
• Abbreviated New Drug Application (ANDA)

Representative Matters

• Sepracor Inc. v. Teva Pharmaceuticals USA, Inc., et al., Case No. 09-CV-1302 (DMC)(D NJ). Patent infringement action regarding Wockhardt USA LLC's ANDA to make a generic version of Sepracor's insomnia product Lunesta®, the active ingredient of which is eszopiclone.
• Merck & Co., Inc. v. Sandoz, Inc., D. NJ. Case No. 3:09-cv-00890-MLC-LHG. Patent infringement action regarding Sandoz's ANDA to make a generic version of Merck's antinausea product Emend®, the active ingredient of which is aprepitant.
• Alcon Research, Ltd. et al. v. Sandoz, Inc., Case No. 09-CV-0103 (LJM)(SD IN). Patent infringement action regarding Sandoz's ANDA to make a generic version of Alcon's ophthalmic product Patanol®, the active ingredient of which is olopatadine hydrochloride.
• Aventis Pharma S.A. and Sanofi-Aventis U.S., LLC v. Apotex Inc. and Apotex Corp., Case No. 08-496 (GMS) (D. Del). Patent infringement action regarding Apotex's ANDA to make a generic version of Sanofi-aventis anti-cancer product Taxotere®, the active ingredient of which is docetaxel.
• Medicis Pharmaceutical Corp. v. Sandoz, Inc. et al., Case No. 09-033 (JJF) (D Del.). Patent infringement action regarding Sandoz's ANDA to make a generic verison of Medicis's acne product Solodyn®, the active ingredient of which is minocycline hydrochloride.
• Endo Pharmaceuticals Inc. et al. v. Sandoz, Inc., Case Nos. 08-534 and 08-970 (KSH) (D Del.). Patent infringement action regarding Sandoz's ANDA to make a generic verison of Endo's pain product Opana® ER, the active ingredient of which is oxymorphone hydrochloride.
• Aventis Pharmaceuticals, Inc. et al. v. Barr Laboratories, Inc. et al., Case No. 01-3627-JAG (D NJ). Patent infringement action regarding Barr Laboratories' ANDA to make a generic version of Aventis's allergy products Allegra® and Allegra-D®, the active ingredient of which is fexofenadine hydrochloride.
• Eli Lilly & Co. v. Barr Laboratories, Inc., Case No. 02-1844-SEB (SD IN). Patent infringement action regarding Barr Laboratories' ANDA to make a generic version of Lilly's osteoporosis product Evista®, the active ingredient of which is raloxifene hydrochloride.
• Ferring B.V. et al. v. Barr Laboratories, Inc., Case No. 02-9851 (SD NY). Patent infringement action regarding Barr Laboratories' ANDA to make a generic version of Ferring's urinary incontinence product DDAVP®, the active ingredient of which is desmopressin acetate.
• Bayer Schering AG, et al. v. Barr Laboratories, Inc., Case No. 05-2308-JPS-ES(D.N.J.) Patent infringement action regarding Barr Laboratories' ANDA to make a generic version of Bayer Schering's oral contraceptive Yasmin®, the active ingredient of which is drospirenone.

Professional Activities

• American Intellectual Property Law Association
• American Inns of Court
• Biotechnology Industry Organization

Admissions

• District of Columbia
• U.S. Patent and Trademark Office
• U.S. Court of Appeals for the Federal Circuit

Education

• University of Akron School of Law, J.D., 1999
• University of Texas at Austin, Ph.D., Organic Chemistry, 1991
• Ohio State University, B.S., Chemistry, 1987

Experience

• Duane Morris LLP
  - Partner, 2008-present
• Sterne, Kessler, Goldstein & Fox PLLC
  - Associate/Director, 1998-2008
• Oldham & Oldham Co., LLP
  - Patent Agent/Law Clerk, 1996-1998

Selected Publications

• "Takeda V. Mylan — Keeping Your Ducks In A Row," Law 360, January 13, 2009
• "Obviousness of Chemical Compounds: The Lead Compound Concept," Intellectual Property Today, July 2007

Selected Speaking Engagements

• "Biosimilars and Follow-On Biologics," Licensing Executives Society, Chicago, May 2008